ORIGINAL RESEARCH article
Front. Immunol.
Sec. Vaccines and Molecular Therapeutics
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1626422
Autovaccine immunoprophylaxis in patients with neurogenic bladder experiencing recurrent urinary tract infections
Provisionally accepted
Miguel Ángel Bonillo García*
Domingo Guzmán Ordaz-JuradoJuan Ortiz-SalvadorJosep Oriol Colet-GuitertEduardo Morán-PascualEsther Martínez-CuencaSalvador Arlandis-Guzmán- La Fe Hospital, Valencia, Spain
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Neurogenic Bladder (NB) patients are highly susceptible to recurrent urinary tract infections (UTIs), often requiring repeated hospitalizations and prolonged antibiotic use. Current preventive strategies, including long-term antibiotics, frequently fail due to resistance and limited efficacy. Autovaccination, a form of personalized immunoprophylaxis using inactivated patientspecific bacterial strains, has shown potential in reducing UTI recurrence but has not been well studied in NB populations.A prospective, single-center study was conducted at the Hospital Universitari i Politécnic La Fe València, Spain. Eligible participants were individuals of any gender, aged between 18 and 65 years, with a confirmed diagnosis of NB. They were required to have experienced recurrent UTIs within the past twelve months, despite having undergone a six-month regimen of prophylactic antibiotics without success.Participants received a sublingual bacterial autovaccine (Uromune®) prepared from uropathogens isolated from their own urine cultures. Primary outcomes included changes in hospitalization and emergency admission rates, while secondary outcomes assessed UTI-free time and patient-reported outcomes using validated instruments.The study included 71 adult NB patients with recurrent UTIs. Autovaccination significantly reduced hospitalizations (from 1.76 ± 3.47 to 0.78 ± 1.38, p < 0.001) and emergency admissions (from 8.62 ± 6.35 to 3.93 ± 4.48, p < 0.001). At 3, 6, 9, and 12 months post-treatment, UTI-free rates were 69.1%, 42.6%, 29.4%, and 20.6%, respectively. Most patients reported high satisfaction and perceived clinical improvement.Conclusions: Autovaccination appears to be a promising strategy for reducing the burden of recurrent UTIs in NB patients, with high patient satisfaction and fewer hospital visits. These findings
Keywords: Autovaccination, Emergency admissions, Hospitalization, neurogenic bladder, Urinary Tract Infections
Received: 10 May 2025; Accepted: 10 Jul 2025.
Copyright: © 2025 Bonillo García, Ordaz-Jurado, Ortiz-Salvador, Colet-Guitert, Morán-Pascual, Martínez-Cuenca and Arlandis-Guzmán. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Miguel Ángel Bonillo García, La Fe Hospital, Valencia, Spain
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.